Abstract:Cancer immunotherapy using cytotoxic T cells demonstrates dramatic survival benefits in lymphomas, but its efficacy in solid tumors is limited. Here, we investigated the possibility of using cytotoxic T cells to treat malignant Schwannoma, a rare but aggressive nerve sheath tumor, by examining the native T-cell immunity in the host. We found that compared to CD8+ T cells from healthy controls or benign Schwannoma patients, the CD8+ T cells from malignant Schwannoma patients were present at normal frequencies but were substantially enriched with PD-1-TIM-3+ and PD-1+TIM-3+ cells. Compared to the PD-1-TIM-3- CD8+ T cells, the PD-1-TIM-3+ and PD-1+TIM-3+ CD8+ T cells presented significantly lower proliferation capacity, reduced interleukin 2 and interferon gamma expression, and/or dramatically decreased perforin and granzyme B secretion, indicating a whole-spectrum immunosuppression and reduced cytotoxicity. TIM-3 expression alone was associated with lower proliferation and less perforin and granzyme B secretion, whereas PD-1 expression alone was not associated with functional impairments, suggesting that TIM-3 expression was a better marker of exhausted CD8+ T cells. The expression of galectin 9, a TIM-3 ligand, in CD4+ Th cells was significantly elevated in malignant, but not benign, Schwannoma patients and were enriched in CD25+ Treg cells. Both the PD-1-TIM-3+ and PD-1+TIM-3+ CD8+ T cells responded to Treg-mediated and galectin 9-mediated suppression, whereas the PD-1+TIM-3- CD8+ T cells only responded to Treg-mediated suppression. In resected tumors, the malignant Schwannomas had more tumor-infiltrating CD4+ and CD8+ T cells than the benign Schwannomas, but a large fraction of these tumor-infiltrating CD4+ and CD8+ T cells expressed PD-1 and/or TIM-3, which indicated that their antitumor immunity was compromised. Together, our results suggested that PD-1 and TIM-3 blockade might be necessary in developing effective immunotherapeutic strategies in malignant Schwannoma, in which TIM-3 may play a more important role.

TIM-3 plays a more important role than PD-1 in the functional impairments of cytotoxic T cells of malignant Schwannomas

PUB044 TIM-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes

T Cell Immunoglobulin and Mucin-Domain Containing-3 in Non-Small Cell Lung Cancer

TIM-3, a Promising Target for Cancer Immunotherapy

Tim-3 Expression Predicts the Abnormal Innate Immune Status and Poor Prognosis of Glioma Patients

Circulating and Tumor-Infiltrating Tim-3 in Patients with Colorectal Cancer.

Cancer cell intrinsic TIM-3 induces glioblastoma progression

T-cell immunoglobulin mucin 3 blockade drives an antitumor immune response in head and neck cancer.

Expression and clinical significance of Tim-3 on CD8 +T cell from peripheral blood of melanoma patients

Glial TIM-3 Modulates Immune Responses in the Brain Tumor Microenvironment

TIM-3 Expression Characterizes Regulatory T Cells in Tumor Tissues and is Associated with Lung Cancer Progression

Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer

TIM-3/CD68 double-high expression in Glioma: Prognostic characteristics and potential therapeutic approaches

Blockade of TIM3 Relieves Immunosuppression Through Reducing Regulatory T Cells in Head and Neck Cancer.

Targeting PD-1 and Tim-3 Pathways to Reverse CD8 T-Cell Exhaustion and Enhance Ex Vivo T-Cell Responses to Autologous Dendritic/Tumor Vaccines

Spatial distribution and functional analysis define the action pathway of Tim-3/Tim-3 ligands in tumor development

Genetic Mutations of Tim-3 Ligand and Exhausted Tim-3+ CD8+ T Cells and Survival in Diffuse Large B Cell Lymphoma

Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patients

TIM-3 restrains anti-tumour immunity by regulating inflammasome activation

TIM-3 as a promising target for cancer immunotherapy in a wide range of tumors

TIM-3 As a Target for Cancer Immunotherapy and Mechanisms of Action.